SAN FRANCISCO, Dec. 23, 2025 (GLOBE NEWSWIRE) -- National investor rights law firm Hagens Berman alerts INSP investors to the pending securities class action lawsuit against Inspire Medical Systems, Inc. (NYSE: INSP). The firm is urging INSP investors who suffered substantial losses to contact attorneys before the January 5, 2026, Lead Plaintiff Deadline.

image for news INSP DEADLINE ALERT: $42.04 Stock Drop at Inspire Medical Systems (INSP) Triggers Securities Fraud Lawsuit Over Concealed Medicare Billing Software Failures & Inspire V Inventory Glut - Hagens Berman

Micron Stock: Buy Now Before It's Too Late — Positive

MU   Seeking Alpha — December 23, 2025

MU has continued its surge to all-time highs. Strong earnings and rising memory prices are fueling upward momentum. Despite the run-up, the stock likely has more room to run in 2026.

image for news Micron Stock: Buy Now Before It's Too Late

Alphabet unit Waymo said on Tuesday it will expand first responder engagement, improve its emergency response protocols and roll out updates to allow its vehicles to navigate intersections more decisively, following incidents of stalled Waymo robotaxis after a San Francisco power outage.

image for news Waymo vows to improve emergency response protocols after San Francisco power outage

Oil Slips; Prices Likely to Remain Volatile — Neutral

BNO  DBO  GUSH  IEO  OIH  OIL  PXJ  UCO  USO  XOP   WSJ — December 23, 2025

Oil slipped in early Asian trade. Prices were likely to remain volatile, with moves dominated by geopolitical developments, Kudotrade said.

image for news Oil Slips; Prices Likely to Remain Volatile

RenaissanceRe's Preferred Stocks Look Undervalued — Positive

RNR   Seeking Alpha — December 23, 2025

RenaissanceRe Holdings offers two investment-grade preferred stocks, RNR.PR.G and RNR.PR.F, both trading below par and near historical lows. RNR.PR.G and RNR.PR.F provide higher yields and capital appreciation potential compared to RNR's OTC bonds, with spreads to Treasuries of 1.77% and 1.59%, respectively. RNR maintains strong financials: $54.5B in assets, $18.97B equity, and investment-grade credit ratings from major agencies.

image for news RenaissanceRe's Preferred Stocks Look Undervalued

A preliminary injunction in federal court cited the First Amendment, handing a win to tech companies like Apple and Google.

image for news Texas Age-Verification Law for App Stores Is Blocked, a Win for Apple and Google

NEW YORK , Dec. 23, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Heritage Commerce Corp (NASDAQ: HTBK) related to its sale to CVB Financial Corp. Under the terms of the proposed transaction, Heritage shareholders are expected to receive 0.6500 shares of CVB common stock for each share of Heritage.

image for news SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Heritage Commerce Corp (NASDAQ: HTBK)

Limoneira Company (LMNR) Q4 2025 Earnings Call Transcript — Neutral

LMNR   Seeking Alpha — December 23, 2025

Limoneira Company (LMNR) Q4 2025 Earnings Call Transcript

image for news Limoneira Company (LMNR) Q4 2025 Earnings Call Transcript

VTWV: Lack Of Profitability Filter Is A Concern — Negative

VTWV   Seeking Alpha — December 23, 2025

The Vanguard Russell 2000 Value Index ETF offers low-cost, broad small-cap value exposure but lacks a profitability filter, increasing portfolio risk. VTWV allocates heavily to micro-cap, unprofitable companies, resulting in negative return on invested capital and below-peer profitability metrics. Peers like FNDA, AVUV, and VBR, which screen for profitability or cash flows, deliver superior volatility-adjusted returns and higher Sharpe ratios than VTWV.

image for news VTWV: Lack Of Profitability Filter Is A Concern

Focus: Lilly, Novo lock horns in India's obesity drug race — Neutral

LLY  NVO   Reuters — December 23, 2025

Global pharma giants Eli Lilly and Novo Nordisk are scrambling to cement their lead in India's booming obesity drug market before cheaper generic versions hit shelves in March next year.

image for news Focus: Lilly, Novo lock horns in India's obesity drug race

International Seaways, Inc. is not fully insulated from headwinds, but its prudent fleet management ensures efficiency and profitability. Its well-balanced exposure to spot and time charter rates provides it with enough flexibility and security to protect its topline performance. Its robust Balance Sheet ensures it can sustain its increasing operating capacity and dividend payments.

image for news International Seaways: Strategic Vessel Management And Fundamental Stability Amid Oil Market Volatility

The company's first-ever chief brand officer, Asad Ayaz, is Bob Iger's pick to depoliticize America's best-known entertainment company.

image for news The Marketing Master Trying to Make Us Fall in Love With Disney Again

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Headline of release should read: Klarna Group plc Securities Class Action Result of Understated Risks and Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC (instead of Klarna Group plc Securities Fraud Class Action Result of Understated Risks and Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC). The updated release reads: KLARNA GROUP PLC SECURITIES CLASS ACTION RESULT OF UNDERS.

image for news CORRECTING and REPLACING Klarna Group plc Securities Class Action Result of Understated Risks and Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

Why Intuitive Machines Stock Slipped on Tuesday — Neutral

LUNR   The Motley Fool — December 23, 2025

Profit-taking quashed a mini-rally for space stocks. They were flying higher in recent days because of a political development.

image for news Why Intuitive Machines Stock Slipped on Tuesday

AQVESME is the only FDA-approved medicine for anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia Marketed under AQVESME brand name in the U.S. for thalassemia indication; PYRUKYND® (mitapivat) remains the U.S. brand name for PK deficiency indication AQVESME expected to be available in late January 2026, following AQVESME REMS program implementation Company will host investor conference call and webcast tomorrow, December 24 at 8:00 a.m. ET CAMBRIDGE, Mass.

image for news U.S. FDA Approves Agios' AQVESME™ (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-Thalassemia

Carvana's Comeback: Structural Growth, S&P 500 Inclusion, But Pricey Valuation — Positive

CVNA  IVV  SPLG  SPXL  SPY  SSO  UPRO  VOO   Seeking Alpha — December 23, 2025

Carvana has staged a dramatic turnaround, rising over 12,000% from 2022 lows at $3.56 to $450 and achieving S&P 500 inclusion. Idiosyncratic Revenue Growth: Q3 2025 revenue grew 54% YoY to $5.65B, outpacing the broader U.S. used-car market and traditional competitors, reflecting true Carvana-specific volume expansion. Operating Leverage & Margins: Semi-fixed SG&A and lower COGS per unit position Carvana to convert revenue growth into outsized EBIT gains, highlighting the potential for margin expansion as scale increases.

image for news Carvana's Comeback: Structural Growth, S&P 500 Inclusion, But Pricey Valuation

Altimmune: Pemvidutide's 48-Week Data Confirms The Market's Smokescreen — Positive

ALT   Seeking Alpha — December 23, 2025

Altimmune delivered strong 48-week Phase IIb data for pemvidutide in MASH, supporting progression to Phase III. Pemvidutide showed durable, dose-dependent improvements in non-invasive fibrosis markers and consistent safety, with weight loss reaching 7.5% at 1.8 mg. Regulatory alignment for a Phase III trial targeting accelerated approval appears promising, with biopsy-based endpoints and a planned 2.4 mg dose.

image for news Altimmune: Pemvidutide's 48-Week Data Confirms The Market's Smokescreen

Dan Ives talks Nvidia, Oracle, Palantir, and AI. — Neutral

NVDA  ORCL  PLTR   Yahoo Finance — December 23, 2025

About Yahoo Finance: Yahoo Finance provides free stock ticker data, up-to-date news, portfolio management resources, comprehensive market data, advanced tools, and more information to help you manage your financial life. - Get the latest news and data at finance.yahoo.com - Download the Yahoo Finance app on Apple (https://apple.co/3Rten0R) or Android (https://bit.ly/3t8UnXO) - Follow Yahoo Finance on social: X: http://twitter.com/YahooFinance Instagram: https://www.instagram.com/yahoofinance/?hl=en TikTok: https://www.tiktok.com/@yahoofinance?lang=en Facebook: https://www.facebook.com/yahoofinance/ LinkedIn: https://www.linkedin.com/company/yahoo-finance

image for news Dan Ives talks Nvidia, Oracle, Palantir, and AI.

Why Ramaco Resources Trounced the Market Today — Positive

METC   The Motley Fool — December 23, 2025

It just announced a shareholder-pleasing measure. It's authorized to spend up to $100 million on this.

image for news Why Ramaco Resources Trounced the Market Today

SAN FRANCISCO, Dec. 23, 2025 (GLOBE NEWSWIRE) -- A securities class action styled Nayak v. Klarna Group plc, et al.

image for news Klarna Group (KLAR) Hit With IPO-Related Securities Class Action Amid 102% Spike in Credit Loss Provision, Questions About Risk-Related Trends Disclosures – Hagens Berman